Related Experiment Videos
Benign nonampullary duodenal neoplasms.
Alexander Perez1, John R Saltzman2, David L Carr-Locke2
1Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St., 02115, Boston, MA.
Summary
Benign duodenal neoplasms (BDNs) are uncommon. Endoscopic management offers minimal morbidity for most BDNs, but adenoma patients require systematic follow-up due to recurrence risks.
Area of Science:
- Gastroenterology
- Surgical Oncology
- Oncology
Background:
- Benign duodenal neoplasms (BDNs) are rare, and established optimal management strategies are lacking.
- This study reviews institutional experience with BDN treatment over a decade.
Purpose of the Study:
- To evaluate the management and outcomes of benign duodenal neoplasms.
- To compare the efficacy and safety of operative versus non-operative treatment modalities.
Main Methods:
- Retrospective analysis of 62 patients treated for BDNs between January 1990 and January 2000.
- Histological classification of lesions, including adenomas, Brunner's gland tumors, inflammatory polyps, and hamartomas.
- Evaluation of factors influencing surgical intervention, such as polyp size and endoscopic ultrasound findings.
Main Results:
- Forty-seven patients were managed nonoperatively, while 15 underwent surgery.
- Endoscopic resection resulted in 2% major morbidity, significantly lower than the 33% observed in surgical cases (P = 0.002).
- Recurrence was observed in 19.4% of adenoma patients within a median of 12 months.
Conclusions:
- Most benign duodenal neoplasms can be effectively managed with endoscopic techniques, minimizing patient morbidity.
- Surgical intervention is indicated for specific cases, such as large or submucosally penetrating lesions.
- Regular follow-up is crucial for patients treated for duodenal adenomas to monitor for potential recurrences.